Despite continuous improvements in stroke care over the past decades, contraindications of the currently approved recanalization therapies, such as an increased bleeding risk or the occlusion of only small vessels, prevent ~70% of all stroke patients to receive either intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA, Alteplase) or endovascular therapy (EVT), i.e., mechanical thrombectomy [1]. The gene discussed is PLAT; the disease is Stroke.